Asymmetric dimethylarginine is associated with carotid atherosclerosis in patients with essential hypertension

Area of Science:

• Cardiovascular Medicine
• Hypertension Research
• Biomarker Discovery

Background:

• Essential hypertension is a significant risk factor for cardiovascular diseases.
• Carotid atherosclerosis, a manifestation of atherosclerosis, contributes to stroke risk.
• Asymmetric dimethylarginine (ADMA) is an endogenous inhibitor of nitric oxide synthase, implicated in endothelial dysfunction.

Purpose of the Study:

• To investigate the association between plasma ADMA levels and carotid atherosclerosis.
• To determine if ADMA is an independent predictor of carotid plaque formation in patients with essential hypertension.

Main Methods:

• A case-control study involving 182 patients with never-treated essential hypertension and 182 age-matched healthy controls.
• Measurement of plasma ADMA levels.
• Assessment of carotid atherosclerosis using mean intima-media thickness (IMT) and plaque score.

Main Results:

• Hypertensive patients exhibited significantly higher plasma ADMA levels, mean IMT, and plaque scores compared to controls.
• Plasma ADMA levels showed a positive correlation with mean IMT.
• ADMA was identified as a significant independent predictor of carotid plaque formation (plaque score ≥1.1) via logistic regression analysis.

Conclusions:

• Elevated ADMA levels are associated with the presence and severity of carotid atherosclerosis in essential hypertension.
• ADMA may play a crucial role in the pathogenesis of atherosclerosis in hypertensive individuals.
• ADMA could serve as a potential biomarker for assessing cardiovascular risk in patients with essential hypertension.